多发性骨髓瘤p16基因甲基化与其预后的相关性Relationship between Methylation of p16 Gene and Prognosis of Multiple Myeloma
徐文;卢爱萍;贾娇源;梁新悦;张伟;朱秀云;刘建慧;
摘要(Abstract)：
目的探讨多发性骨髓瘤p16基因甲基化与其预后之间的相关性。方法采用甲基化敏感的限制性内切酶联合聚合酶链反应方法(REP法),检测52名多发性骨髓瘤(MM)患者骨髓细胞p16基因第1外显子的甲基化状态,并检测存在p16基因第1外显子甲基化的MM患者p16基因的mRNA转录水平。对这52名患者的临床资料及预后因素进行分析。结果52名MM患者中,p16基因启动子区第1外显子甲基化率为53.84%(28/52)。存在p16基因第1外显子甲基化的MM患者中,p16基因mRNA阴性率为75%。p16基因甲基化患者的预后不良因素明显高于非甲基化患者。结论多发性骨髓瘤p16基因甲基化与其预后有关。
关键词(KeyWords)： 多发性骨髓瘤;p16基因;甲基化;预后
基金项目(Foundation): 吉林省科技厅基金资助项目(20010535).
作者(Authors): 徐文;卢爱萍;贾娇源;梁新悦;张伟;朱秀云;刘建慧;
DOI: 10.13200/j.cjb.2007.12.30.xuw.022
参考文献(References)：
- [1]Chim CW,Wong YL,Fung TK,et al.Methylation profiling in multiple myeloma.Leukemia Res,2004,28(4):379-385.
- [2]Patrizia C,Giuliana F,Rossana P,et al.Analysis of MTHFR polymor-phisms and P16methylation andtheir correlation with clinical-biological features of multiple myeloma.Ann Hematology,2006,85(7):474-477.
- [3]San-Miguel J,Garcia-Sanz R,L幃pez-Pérez R.Analysis of methylation pat-ternin multiple myeloma.Acta Haematologica.2005,114(Suppl1):23-26.
- [4]张之南,沈悌.血液病诊断及疗效标准.第2版.北京:科学出版社,1998.373～379.
- [5]Baur A,Shaw P,Burrin T,et al.Frequent methylation silencing of p15INK4b(MTS2)and p16INK4a(MTS1)in B-cell and T-cell lyphomas.Blood,1999,94(5):1773-1781.
- [6]闫骅,吴文,赵维莅,等.多发性骨髓瘤的预后和多因素模型的建立.肿瘤,2003,23(4):312～314.
- [7]Grana X,Reddy EP.Cell cycle control in mammalian cells:role of cy-clins,cyclin dependent kinases(CDKS),growthsuppressor genes and cy-clin-dependent kinase inhibitor(CKIS).Oncogene,1995,11(2):211-219.
- [8]Liggett WHJr,Sidransky D.Role of the p16tumor suppressor gene in cancer.J Clin Oncol,1998,16(3):1197-1206.
- [9]Serrano M,Lee H,Chin L,et al.Role of the INK4a locus in tumor sup-pression and cell mortality.Cell,1996,85(1):27-37.
- [10]Urashinma M,DeCaprio JA,Chauhan D,et al.p16INK4Apromotes dif-ferentiation andinhibits apoptosis of JKB acute lymphoblastic leukemia cells.Blood,1997,90(10):4106-4115.
- [11]Gonzalez M,Mateos MV,Garcia-Sanz R,et al.De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis.Leukemia,2000,14(1):183-187.
- [12]Kamer A,Schultheis B,Bergmann J,et al.Alteration of the cyclin D1/pRb/p16INK4Apathway in multiple myeloma.Leukemia,2002,16(9):1844-1851.
- [13]Mmaria V,Mateos,Ramo’n Garc.y.a-Sanz,et al.Methylationis aninac-tivating mechanismof the p16gene in multiple myeloma associated with high plasma cell proliferation and short survival.BritishJ Haematology,2002,118(4):1034-1040.